Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

An announcement from Perspective Therapeutics ( ($CATX) ) is now available. On December 1, 2025, Perspective Therapeutics updated its corporate ...

TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...

As of that DCO, safety findings based on 55 patients who had received at least one treatment showed [²¹²Pb]VMT-α-NET continued to demonstrate a favorable safety profile, with no dose-limiting ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain ...

Preliminary Activity Analysis In the 15 efficacy-evaluable patients in the 120 mg cohort, the majority of which received an effective dose of 80 mg QD, enozertinib demonstrated strong systemic and CNS ...

Mysterious footage released by Bethesda has sparked discussion among fans about where The Elder Scrolls 6 will be set.

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

Bank of America Leveraged Finance Conference December 2, 2025 10:50 AM ESTCompany ParticipantsNicole Maggio - Senior ...